Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech World Maldives.
Press releases published on August 5, 2025
Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12
DALLAS, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the …
Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights
Three presentations at ADA 2025 highlighted the therapeutic potential of icovamenib across multiple aspects of metabolic health: In patients with type 2 diabetes (T2D) not achieving glycemic targets, icovamenib demonstrated durable HbA1c reduction and …
Astera Labs Announces Financial Results for the Second Quarter of Fiscal Year 2025
Record quarterly revenue of $191.9 million, up 20% QoQ and 150% YoY, and record operating cash flow generation of $135.4 million Industry leading PCIe 6 connectivity portfolio ramping in volume on customized rack-scale AI systems Scorpio Fabric Switch …
Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Phase 1 trial of TERN-701 in chronic myeloid leukemia (CML) enrolling well; efficacy and safety data including 6-month major molecular response (MMR) rates expected in 4Q25 Phase 2 trial of TERN-601 for obesity completed enrollment; 12-week efficacy, …
Datadog to Present at Upcoming Investor Conferences
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Datadog, Inc. (NASDAQ:DDOG), the monitoring and security platform for cloud applications, today announced that management will present at the following investor conferences. The Keybanc Technology Leadership …
Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum
Highlights Second quarter 2025 revenue of $213.1 million increased by 1% year-over-year. Excluding previously discussed headwinds1 of $9.5 million, revenue increased 5% year-over-year. Second quarter 2025 hereditary cancer testing revenue and volume in …
Rumble and Cumulus Media Announce Joint Strategic Partnership
Longboat Key, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Rumble (NASDAQ:RUM), the high-growth video-sharing platform and cloud services provider empowering creators and brands, and Cumulus Media (OTCQB: CMLS), one of the largest audio creators and distributors …
Treace Announces Peer-Reviewed Publication of Four-Year Results of the ALIGN3D™ Lapiplasty® Multicenter Prospective Clinical Study
PONTE VEDRA, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, …
Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results
SEATTLE, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products …
AvePoint to Participate in Upcoming Investor Conferences
JERSEY CITY, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- AvePoint (Nasdaq: AVPT), the global leader in data security, governance and resilience, today announced that members of the Company’s executive management team will present at the following investor …
Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita® Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure
Two-year follow-up in Germany Real-World Registry study showed median 9.6% weight loss and 1.6% HbA1c reduction after a single Revita procedure in participants with type 2 diabetes, with no device- or procedure-related serious adverse events to date New …
Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025
SCOTTSDALE, Ariz., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug …
Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne
Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne Year-over-year Q2 revenues increased by 20% to $26.6 million Adjusted EBITDA …
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to …
BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates
- As of August 1, 2025, 3,751 unique patient prescriptions have been written by 1,074 unique prescribers, representing an accelerating launch driven by strong month over month growth in the crucial treatment naïve patient segment - $110.6 million in total …
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Generated Product Revenues of $79 million for the Three Months Ended June 30 Awarded Additional Development Funding of $27 million under the BARDA 19C Contract during the Three Months Ended June 30 Corporate …
Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025
NEWTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the …
Day One Reports Second Quarter 2025 Financial Results and Corporate Progress
OJEMDA™ (tovorafenib) net product revenue of $33.6 million in Q2 2025, a 10% quarter-over-quarter increase OJEMDA full-year 2025 net product revenue expected to be $140 to $150 million Ended the second quarter with $453.1 million in cash, cash equivalents …
Pacira BioSciences Reports Second Quarter 2025 Financial Results
-- Solid execution across corporate, clinical and commercial initiatives -- -- Several key milestones advance 5x30 path to growth -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. ( …
IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call
Investors are reminded that Shareholders of record as of August 7, 2025, will receive a 15% stock dividend payment LAWRENCEVILLE, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its …